- About Us
- Products in Development
SAN DIEGO, Aug. 7, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem"), announced today that its Chief Medical Officer, Kelly Culwell, MD, will present at the #BlogHer18 Creators Summit, presented by SheKnows Media, on Wednesday, August 8, 2018 at 4:05 p.m. EDT in New York City.
Dr. Culwell, aka Dr. Lady Doctor, will address an audience of over 2,000 health and lifestyle bloggers and social media influencers on the topic of unmet needs in women's reproductive healthcare including contraception, prevention of sexually transmitted infections like chlamydia, and bacterial vaginosis.
In addition to this presentation, Dr. Culwell will launch a sexual and reproductive health platform, House Call with Dr. Lady Doctor, at the #BlogHer18 Creators Summit. Through this educational resource, Dr. Culwell hopes to bridge the conversational gap between healthcare providers and patients.
"While women make up 51% of the U.S. population, there is clearly a need for a clinically relevant, approachable and sometimes humorous sexual health resource," Dr. Culwell noted. "Dr. Lady Doctor is intended to provide women with critical knowledge and resources that will enable and empower them to have informed conversations with their healthcare provider."
Dr. Culwell is an OB/GYN who for over 15 years has specialized in women's health and contraceptive research and overseen large contraceptive clinical trials globally. She was previously the Senior Medical Advisor for the International Planned Parenthood Federation (IPPF) and served as a Medical Officer with the World Health Organization (WHO).
The development of the House Call with Dr. Lady Doctor educational resource was funded by Evofem Biosciences, a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. Evofem is leveraging its proprietary Multi-purpose Prevention Technology vaginal gel to develop Amphora, which if approved, will be the first non-hormonal, on demand, prescription contraceptive for women. The Company is also focusing on other areas of great unmet need for women, with a Phase 2b study for prevention of urogenital chlamydia underway. For more information regarding Evofem, visit www.evofem.com.
Statements in this press release about the Company's future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the Company's control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in the Company's filings with the SEC, including its Quarterly Report on Form 10-Q filed with the SEC on May 14, 2018, and include but are not limited whether Evofem's product candidates will receive approval from regulatory agencies on a timely basis or at all; risks and uncertainties associated with the Phase 3 clinical trial of Amphora and the Phase 2b STI clinical trial. Forward-looking statements in this press release are made as of August 7, 2018, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.
Chief Client Service Officer, Partner
O: (646) 599-8601
M: (646) 247-3405
SOURCE Evofem Biosciences, Inc.